Latest Research

New BRCA Research Opportunities for Men

 The National Institutes of Health (NIH) is seeking male participants (30-75) with a genetic risk factor for developing prostate cancer. The study includes regular MRI screening and biopsies for those showing irregular tests. For more information, please contact Anna Couvillon at the National Institutes of Health.





Graphic Novel Study

Are you a male at high risk for developing hereditary cancer but has not been diagnosed with cancer? Do you have a family history of carrying a BRCA1/2 genetic mutation? Do you feel you have information to make informed health and family decisions about your future? Are you interested in sharing your experiences to help others?

Participate in a 60-minute online interview. Participants will receive a $30 Amazon gift card. If you are interested in this research opportunity, please the study coordinator Ms. Lexi Ingle at



Expert Interview: BRCA and Male Breast Cancer

BCRF investigator Dr. Ken Offitt discusses how gene mutations can influence risk in men, and how those who carry BRCA can protect themselves and their families. Check out this short video:

Population BRCA testing in Ashkenazi Jews reduces anxiety and does not adversely affect psychological health or quality of life

Study indicates that population‐based Ashkenazi Jewish BRCA testing does not adversely affect long‐term psychological wellbeing or quality‐of‐life, decreases anxiety and could identify up to 150% additional BRCA carriers.

81 Attitude towards and factors affecting uptake of population based BRCA testing in Ashkenazi Jews: a cohort study

BRCA testing in the Ashkenazi Jewish population shows high acceptability. Pre-test counselling increases awareness of disadvantages/limitations of BRCA-testing, influencing the final cost-benefit perception and decision-making of undergoing testing.

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.